



06/28/04

1FW

CASE 4-31394B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV45786782PLUS</u> Express Mail Label Number	<u>6/25/04</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
RONALD EDWARD STEELE
APPLICATION NO: 10/826,106
FILED: APRIL 15, 2004
FOR: COMBINATION OF ORGANIC COMPOUNDS

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The listed references, except for reference AP are of record in parent Application No. 10/149,107 filed August 27, 2002, and copies are available therein. However, applicant is willing to send copies of any or all of these references at the Examiner's request.

A copy of reference AP, WO01/76574 A2, is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7831



Gregory D. Ferraro
Attorney for Applicant
Reg. No. 36,134

Date: 6/25/04



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31394B
APPLICATION NO.
10/826,106
APPLICANT
Ronald Edward Steele
FILING DATE
APRIL 15, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,997,948	3/5/91	Zask et al.	548	183	10/27/89
	AB	5,057,521	10/15/91	Hausler et al.	514	300	9/26/89
	AC	5,252,565	10/12/93	Peet et al.	514	177	9/6/91
	AD	5,906,987	5/25/99	Chwalisz et al.	514	177	3/10/97
	AE	5,972,921	10/26/99	Santti et al.	514	177	12/12/97
	AF	4,889,861	12/1/89	Browne, Leslie J.	514	300	11/13/87
	AG	5,972,921	10/1/99	Santti et al.	514	177	12/12/97
	AH	6,653,306	11/1/03	Alexander et al.	514	234.5	1/9/97
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00/02543	1/20/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 98/03180	1/29/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 99/45779	9/16/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO01/76574 A2	10/18/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Masato et al., "AlGaAs/GaAs Double-Doped Quantum-Well HEMTs for Low Distortion Amplifier", Extended Abstracts of the 1993 International Conference on Solid State Devices and Materials, Japan Soc. Appl. Physics, Tokyo, Japan, pp. 715-717 (1993).
	AS	Chem. Abstracts, File Registry Abstract for Compound RN # 135070-05-02 (2004).
	AT	Derwent Abstract, FR 2,766,821, 2/5/99 - Sanofi SA

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31394B
APPLICATION NO.
10/826,106
APPLICANT
Ronald Edward Steele
FILING DATE
APRIL 15, 2004

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AU	Faggiotto and Paoletti, "Statins and Blockers of the Renin-Angiotensin System. Vascular Protection Beyond Their Primary Mode of Action". Hypertension, Vol. 34, Part II, pp. 987-996 (1999).
	AV	Hagman et al., Journal of Cardiovascular Pharmacology, vol. 29, No. 4, pp. 444-450 (1997)
	AW	Harrison's Principles of Internal Medicine, 9th ed., Isselbacher et al. (eds), published 1980, pages 1035, 1036 and 1299.
	AX	Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al., (eds), Vol. 1, published 1994, page 986
	AY	Jeremic et al., "Effects of a New Angiotensin-Converting Enzyme Inhibitor (Idrapril) in rats with left Ventricular Dysfunction After Myocardial Infarction", J. Cardiovasc. Pharmacol., Vol. 27, No. 3, pp. 347-354 (1996)
	AZ	Johnston et al., "Enzyme-Activated Inhibitors of Steroidal Hydroxylases", J. Steroid Biochem. Molec. biol. Vol. 52, No. 1, pp. 17-34 (1995)
	BA	Makino et al., "Regression of Hypertrophy After Myocardial Infarction is Produced by the Chronic Blockade of Angiotensin Type 1 Receptor in Rats" J. Mol. Cello. Cardiol., Vol. 28, pp. 507-517 (1996)
	BB	Maxfield et al., Diabetologia, vol. 36, no. 12, pp 1230-1237 (1993) XP001053448.
	BC	Patent Abstract of Japan, vol. 1997, no. 7, Yamanouchi, JP 09071586A, July 31, 1997 XP000409466
	BD	The Merck Index, Twelfth Edition, Budavari, editor, Merck & Co. Inc., Whitehouse Station, NJ, p 105 [667. Anastrozole - Japan Abstract]: p 666 [3969. Fadrozole] (1996)
	BE	Viigimaa et al., Cardiovascular Drugs and Therapy, vol. 14, no. 4, pp 447-449 (2000) XP001053452
	BF	
	BG	
	BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.